Multiple factors made Amino Asylum a priority target: marketing products explicitly for human consumption, selling prescription medications without authorization, using trademarked pharmaceutical terms in advertising, ignoring FDA warning letters, and operating at a scale that made the public health risk significant
But the FDA recently reclassified them, so they're no longer an option for most people
p.11 (2009)
doi: 10.1158/1078-0432.CCR-04-0744
It also calls for baseline labs covering fasting glucose, creatinine and eGFR, liver enzymes, a lipid panel and electrolytes, with follow-up roughly every three months, because sustained high protein intake alongside GLP-1 therapy can move kidney markers in susceptible people
Until formal studies confirm long-term outcomes, it remains an exciting but exploratory option in the world of skin boosters